/print certificate. Release date: March 15, 2013; Expiration date: March 15, 2014. Learning Objectives Upon completion of this activity, participants will be able to: Describe the role of oxaliplatin in the management of rectal cancer. Describe the
Search Results
Ludmila Katherine Martin and Tanios Bekaii-Saab
Christina Teng, Venkatesha, Prunella L. Blinman, and Janette L. Vardy
Background Adjuvant oxaliplatin-containing chemotherapy improves survival in patients with colorectal cancer (CRC). 1 Chemotherapy-induced peripheral neuropathy (CIPN) from oxaliplatin can be debilitating and is a reason for early
Natasha Satkunam, Xuejiao Wei, James J. Biagi, Sulaiman Nanji, and Christopher M. Booth
trial demonstrated that the addition of oxaliplatin to 5-FU (FOLFOX) led to improved disease-free survival. 4 Similar findings were observed in a second RCT. 5 Updated analyses of the MOSAIC trial demonstrated oxaliplatin is associated with improved
Deirdre R. Pachman, Kathryn Ruddy, Lindsey R. Sangaralingham, Axel Grothey, Nilay D. Shah, Andreas S. Beutler, Joleen M. Hubbard, and Charles L. Loprinzi
Oxaliplatin-induced peripheral neuropathy is a common toxicity that may last for years, which has resulted in extensive interest in identifying interventions to prevent its occurrence. Administration of intravenous doses of calcium and magnesium
Brittany Bauman, Rosemarie Mick, Eileen Martinez, Theresa M. Lawless, Lindsey Zinck, Paige Sinclair, Mary Fuhrer, Mark O’Hara, Charles J. Schneider, Peter O’Dwyer, John Plastaras, Ursina Teitelbaum, and Kim A. Reiss
Background Oxaliplatin is a commonly used chemotherapy for patients with gastrointestinal cancers. 1 , 2 A unique and common toxicity of oxaliplatin is oral thermal hyperalgesia (OTH), a form of acute neuropathy caused by disruption of voltage
Viola Walter, Daniel Boakye, Janick Weberpals, Lina Jansen, Walter E. Haefeli, Uwe M. Martens, Phillip Knebel, Jenny Chang-Claude, Michael Hoffmeister, and Hermann Brenner
recommended for patients with stage III colon cancer, beginning in the 1990s. In 2004, results from the MOSAIC trial showed that a combination of oxaliplatin with conventional 5-FU/leucovorin (LV) chemotherapy significantly improved 3-year disease
Eric J Roeland, Thomas W. LeBlanc, Kathryn J. Ruddy, Ryan Nipp, Rebecca Clark-Snow, Rita Wickham, Gary Binder, William L. Bailey, Ravi Potluri, Luke M. Schmerold, Eros Papademetriou, and Rudolph M. Navari
+ cyclophosphamide (AC), carboplatin (>14 days apart, as a proxy for AUC ≥4), oxaliplatin (OX), and other non-HEC chemotherapy. We assessed guideline adherence, defined as triple prophylaxis (NK1 RA + 5HT3 RA +dexamethasone) rates at HEC initiation. Results: In 17
Joseph Rosales and Lucille A. Leong
– 1047 . 10 Levi F Perpoint B Garufi C . Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate . Eur J Cancer 1993 ; 29A : 1280 – 1284 . 11
Paul F. Engstrom, Juan Pablo Arnoletti, Al B. Benson III, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Anne Covey, Raza A. Dilawari, Dayna S. Early, Peter C. Enzinger, Marwan G. Fakih, James Fleshman Jr., Charles Fuchs, Jean L. Grem, Krystyna Kiel, James A. Knol, Lucille A. Leong, Edward Lin, Mary F. Mulcahy, Sujata Rao, David P. Ryan, Leonard Saltz, David Shibata, John M. Skibber, Constantinos Sofocleous, James Thomas, Alan P. Venook, and Christopher Willett
metastatic colorectal cancer treated with cetuximab . Ann Oncol 2008 ; 19 : 508 – 515 . 28 Punt CJ Tol J Rodenburg CJ . Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal
Paul F. Engstrom, Juan Pablo Arnoletti, Al B. Benson III, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Anne Covey, Raza A. Dilawari, Dayna S. Early, Peter C. Enzinger, Marwan G. Fakih, James Fleshman Jr., Charles Fuchs, Jean L. Grem, Krystyna Kiel, James A. Knol, Lucille A. Leong, Edward Lin, Mary F. Mulcahy, Sujata Rao, David P. Ryan, Leonard Saltz, David Shibata, John M. Skibber, Constantinos Sofocleous, James Thomas, Alan P. Venook, and Christopher Willett
radiological response in metastatic colorectal cancer treated with cetuximab . Ann Oncol 2008 ; 19 : 508 – 515 . 34 Punt CJ Tol J Rodenburg CJ . Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in
